Page 110 - CIBER-BBN2016-ENG

leaD reSearcher
Schwartz Navarro, Simó
Fundación Hospital Universitario Vall d’Hebron - Institut de Recerca (VHIR) Passeig Vall d’Hebron, 119-129 08035 Barcelona
(+34) 93 489 40 53 [email protected] group Website
GROUP MEMBERS
Staff members: Boullosa Goberna, Ana María | Da Silva Andrade, Fernanda Raquel | Díaz Riascos, Vanessa | González Callejo, Patricia | Lechado Terradas, Anna | Mancilla Zamora, Sandra | Santos Benito, Fernando Fidel
Associated members: Abasolo Olaortua, Ibane | Alijotas Reig, Jaume | Armengol Carrasco, Manuel | Baldrich Rubio, Eva | Espín Basany, Eloy | Fernández Amurgo, Yolanda | López Cano, Manuel | Sayos Ortega, Juan
Contributors: Andretta, Elena | Bazzocco, Sarah | García Aranda, Natalia | García Latorre, Laura
Main lines of research
Our group develops research projects mainly focused on oncology and rare diseases. These projects are conducted around three preferred work areas:
• Area 1: biomarkers and therapeutic targets from suitable experimental models, as molecular
biomarkers, diagnostic providers in biosensors (nanodiagnosis) or for biofunctionalizing new nanomedicines and therapeutic targets for designing new more effective treatments or alternative therapeutic strategies (new nanomedicines).
• Area 2: experimental chemistry and applied nanotechnology, especially enhancing the study of polymeric nanomedicines, through simpler chemical synthesis designs and potential scalability, as well as new experimental genomic therapies (iRNA, artificial non-viral vectors, etc.) and the study of biomedical applications based on nanotechnology (biosensors) and new biomaterials.
• Area 3: Validation of targets and functional studies. This is essential for obtaining concept tests
and preclinical studies of new biomarkers and targets, as well as of new nanomedicines including: biodistribution, toxicity, therapeutic activity, specificity, functional molecular studies, etc., in different in vitro and in vivo experimental models.
110
PROGRAMMES
Nanomedicine